VIA
AUTL

Virtus Investment Advisers’s Autolus Therapeutics AUTL Stock Holding History

Virtus Investment Advisers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52,924
Closed -$86.3K – 470
2025
Q3 		$86.3K Buy
52,924
+9,188
+21% +$17.9K 0.02% 431
2025
Q2 		$99.7K Sell
43,736
-17,291
-28% -$28.6K 0.03% 335
2025
Q1 		$94.6K Buy
+61,027
New +$124K 0.03% 430

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Virtus Investment Advisers's AUTL Position: Q4 2025 in Review

Virtus Investment Advisers sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 52,924 shares — an estimated $86.3K sold.

Virtus Investment Advisers first reported a position in AUTL in Q1 2025 and held it in 3 quarters. The position peaked at $99.7K in Q2 2025. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Virtus Investment Advisers reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 52,924 Autolus Therapeutics shares in Q4 2025, an estimated $86.3K.
  • Virtus Investment Advisers first reported a position in Autolus Therapeutics in Q1 2025 and held it in 3 quarters.
  • Virtus Investment Advisers's Autolus Therapeutics position peaked at $99.7K in Q2 2025.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.